Compare DMRC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRC | QNCX |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.8M | 167.0M |
| IPO Year | N/A | 2019 |
| Metric | DMRC | QNCX |
|---|---|---|
| Price | $5.05 | $0.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $10.00 |
| AVG Volume (30 Days) | 233.8K | ★ 126.7M |
| Earning Date | 02-27-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,663,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.91 | $0.13 |
| 52 Week High | $35.51 | $4.55 |
| Indicator | DMRC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 33.46 | 28.45 |
| Support Level | $5.02 | $0.13 |
| Resistance Level | $5.91 | $0.98 |
| Average True Range (ATR) | 0.41 | 0.36 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 12.24 | 3.49 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.